Efficacy and safety of rituximab for primary nephrotic syndrome with acute kidney injury A two-center prospective cohort study

Efficacy and safety of rituximab for primary nephrotic syndrome with acute kidney injury : A two-center prospective cohort study

Copyright © 2022 Elsevier Inc. All rights reserved.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 246(2023) vom: 28. Jan., Seite 109211
Auteur principal: Xu, Yili (Auteur)
Autres auteurs: Huang, Yiqing, Zhang, Chengning, Sun, Lianqin, Sun, Zhuxing, Wang, Liang, Zhang, Bo, Yuan, Yanggang, Xing, Changying, Mao, Huijuan
Format: Article en ligne
Langue:English
Publié: 2023
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article Research Support, Non-U.S. Gov't Acute kidney injury Nephrotic syndrome Prospective cohort Rituximab Targets driven 4F4X42SYQ6 Immunosuppressive Agents
Accès en ligne Volltext